Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Lung Neoplasms 2Testicular Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 9pembrolizumab 5lenvatinib 5durvalumab 5atezolizumab 5tremelimumab 3fludarabine 3camrelizumab 3apatinib 3Ipilimumab 3Cyclophosphamide 3regorafenib 2Riluzole 2Radiotherapy 2Nivolumab 2Magnetic Resonance Imaging 2Idarubicin 2Blood Specimen Collection 2Biopsy 2yttrium chloride 1trastuzumab deruxtecan 1spartalizumab 1sintilimab 1pertuzumab 1ferric carboxymaltose 1epigallocatechin gallate 1donafenib 1cemiplimab 1brodalumab 1Yttrium-90 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liver Neoplasms × Mesothelin × Clear all
NCT04842812 2024-06-25

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
40 enrolled
BreastCNSGastrointestinalThoracic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡